TRINITY BIOTECH PLC (TRIB) Form 424B5 — Jun 12, 2026
Trinity Biotech plc has filed a prospectus supplement to launch an At-The-Market (ATM) offering program, allowing it to sell up to $4.35 million of its American Depositary Shares through sales agent Lucid Capital Markets. The filing discloses that the company’s net tangible book value is deeply negative at $(4.95) per ADS, meaning new investors will face immediate dilution of $5.62 per share relative to the company’s underlying asset value. The company is in a precarious financial position, carrying over $132 million in total debt against only $7.6 million in cash.
Key figures
- Total Debt
- 132121000
- Cash Position
- 7638000
- Gross Proceeds
- 4352314
- Offering Price
- 0.6642
- Shares Offered
- 6552716
- Outstanding ADSs
- 20250869
- Outstanding Ordinary Shares
- 405017380
- Dilution Per ADSTo New Investors
- 5.62
- Potential Shares From Mi Co Conversion
- 24691358
- Potential Shares From Perceptive Conversion
- 3359019957
Price after filing
Close on the filing date to close N calendar days later (from $0.68). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.